The Medicaid expansions made addiction treatment more accessible but they also made it less costly to obtain the prescription opioids that can trigger an addiction. We investigated the association between the Medicaid expansions and drug-related deaths. We add to the literature by explicitly accounting for the properties of illicit drug markets and by conducting a simulation-based power analysis to assess whether a plausible change in drug-related mortality could be detected with our data. We identify three main challenges in isolating the effect of the Medicaid expansions on drug-related mortality that cannot be sufficiently addressed with current data: (a) nonparallel preexpansion trends in drug-related mortality, (b) the contemporaneous surge in the supply of illicitly manufactured fentanyl, and (c) lack of statistical power. We argue that more comprehensive data are needed to answer this question.
AboukR.PaculaR. L.PowellD. (2019). Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Internal Medicine, 179(6), 805-811. https://doi.org/10.1001/jamainternmed.2019.0272
2.
AlpertA.PowellD.PaculaR. L. (2018). Supply-side drug policy in the presence of substitutes: Evidence from the introduction of abuse-deterrent opioids. American Economic Journal: Economic Policy, 10(4), 1-35. https://www.aeaweb.org/articles?id=10.1257/pol.20170082
3.
AverettS. L.SmithJ. K.WangY. (2019). Medicaid expansion and opioid deaths. Health Economics, 28(12), 1491-1496. https://doi.org/10.1002/hec.3945
4.
BlackB.HollingsworthA.NunesL.SimonK. (2019). The effect of health insurance on mortality: Power analysis and what we can learn from the Affordable Care Act coverage expansions (NBER Working Paper 25568). https://ideas.repec.org/p/nbr/nberwo/25568.html
Centers for Disease Control and Prevention. (2018b). Rising numbers of deaths involving fentanyl and fentanyl analogs, including carfentanil, and increased usage and mixing with non-opioids. https://emergency.cdc.gov/han/han00413.asp
8.
CiccaroneD. (2009). Heroin in brown, black and white: Structural factors and medical consequences in the U.S. heroin market. International Journal of Drug Policy, 20(3), 277-282. https://doi.org/10.1016/j.drugpo.2008.08.003
9.
DartR. C.SurrattH. L.CiceroT. J.ParrinoM. W.SevertsonS. G.Bucher-BartelsonB.GreenJ. L. (2015). Trends in opioid analgesic abuse and mortality in the United States. New England Journal of Medicine, 372(2015), 241-248. https://doi.org/10.1056/NEJMsa1406143
10.
DenhamA.HillE. (2019). Drug and non-drug related mortality in the first four years of the ACA Medicaid expansion [Manuscript in preparation].
11.
DowellD.NoonanR. K.HouryD. (2017). Underlying factors in drug overdose deaths. Journal of the American Medical Association, 318(23), 2295-2296. https://doi.org/10.1001/jama.2017.15971
EvansW. N.LieberE.PowerP. (2019). How the reformulation of oxycontin ignited the heroin epidemic. Review of Economics and Statistics, 101(1), 1-15. https://doi.org/10.1162/rest_a_00755
14.
GladdenR. M.MartinezP.SethP. (2016). Fentanyl law enforcement submissions and increases in synthetic opioid–involved overdose deaths: 27 States, 2013–2014. Morbidity and Mortality Weekly Report, 65(33), 837-843. http://dx.doi.org/10.15585/mmwr.mm6533a2
GruberJ.SimonK. (2008). Crowd-out 10 years later: Have recent public insurance expansions crowded out private health insurance?Journal of Health Economics, 27(2), 201-217. https://doi.org/10.1016/j.jhealeco.2007.11.004
17.
JonesC. M.PaulozziL. J.MackK. A. (2014). Sources of prescription opioid pain relievers by frequency of past-year nonmedical use: United States, 2008-2011. JAMA Internal Medicine, 174(5), 802-803. https://doi.org/10.1001/jamainternmed.2013.12809
18.
Kravitz-WirtzN.DavisC. S.PonickiW. R.Rivera-AguirreA.MarshallB. D. L.MartinsS. S.CerdáM. (2020). Association of Medicaid expansion with opioid overdose mortality in the United States. JAMA Network Open, 3(1), Article e1919066. https://doi.org/10.1001/jamanetworkopen.2019.19066
19.
LipariR. N.HughesA. (2017). How people obtain the prescription pain relievers they misuse (The CBHSQ Report). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.ncbi.nlm.nih.gov/books/NBK424785/
20.
MacleanJ. C.SalonerB. (2019). The effect of public insurance expansions on substance use disorder treatment: Evidence from the Affordable Care Act. Journal of Policy Analysis and Management, 38(2), 366-393. https://doi.org/10.1002/pam.22112
21.
MillerS.WherryL. R. (2017). Health and access to care during the first 2 years of the ACA Medicaid expansions. New England Journal of Medicine, 376(10), 947-956. https://doi.org/10.1056/NEJMsa1612890
22.
MoghtaderiA.PinesJ.ZocchiM.BlackB. (2020). The effect of Affordable Care Act Medicaid expansion on hospital revenue. Health Economics. Advance online publication. https://doi.org/10.1002/hec.4157
23.
O’DonnellJ. K.GladdenR. M.SethP. (2017). Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region: United States, 2006-2015. MMWR Morbidity and Mortality Weekly Report, 66(34), 897-903. https://www.cdc.gov/mmwr/volumes/66/wr/mm6634a2.htm
PatrickS. W.FryC. E.JonesT. F.BuntinM. B. (2016). Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Affairs, 35(7), 1324-1332. https://doi.org/10.1377/hlthaff.2015.1496
26.
PopoviciI.MacleanJ. C.HijaziB.RadakrishnanS. (2018). The effect of state laws designed to prevent nonmedical prescription opioid use on overdose deaths and treatment. Health Economics, 27(2), 294-305. https://doi.org/10.1002/hec.3548
27.
SimonK.SoniA.CawleyJ. (2017). The impact of health insurance on preventive care and health behaviors: Evidence from the first two years of the ACA Medicaid expansions. Journal of Policy Analysis and Management, 36(2), 390-417. https://doi.org/10.1002/pam.21972
28.
TaiB.VolkowN. D. (2013). Treatment for substance use disorder: Opportunities and challenges under the Affordable Care Act. Social Work in Public Health, 28(3-4), 165-174. https://doi.org/10.1080/19371918.2013.758975
29.
WenH.HockenberryJ.BordersT. F.DrussB. (2017). Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Medical Care, 55(4), 336-341. https://doi.org/10.1097/MLR.0000000000000703
YanB. W.SloanF. A.BoscardinW. J.GuoF.DudleyA. (2020). The opioid epidemic blunted the mortality benefit of Medicaid expansion. Medical Care Research and Review. Advance online publication. https://doi.org/10.1177/1077558720919620
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
